Cargando…
Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo
BACKGROUND: Duloxetine has been approved in the United States, European Union and some Asian countries for the treatment of diabetic peripheral neuropathic pain (DPNP). We assessed the efficacy and safety of duloxetine (60 mg once daily) compared with placebo in Chinese patients suffering from DPNP....
Autores principales: | Gao, Y, Guo, X, Han, P, Li, Q, Yang, G, Qu, S, Yue, L, Wang, C-N, Skljarevski, V, Dueñas, H, Raskin, J, Gu, L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682474/ https://www.ncbi.nlm.nih.gov/pubmed/25939897 http://dx.doi.org/10.1111/ijcp.12641 |
Ejemplares similares
-
A Prospective Observational Study Comparing the Efficacy and Safety of Duloxetine and Pregabalin in Diabetic Peripheral Neuropathic Pain
por: Shah, Islam, et al.
Publicado: (2022) -
Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain
por: Skljarevski, Vladimir, et al.
Publicado: (2012) -
Effect of Topical Capsaicin on Painful Sensory Peripheral Neuropathy in Patients with Type 2 Diabetes: A Double-Blind Placebo-Controlled Randomised Clinical Trial
por: Agoons, Batakeh B., et al.
Publicado: (2020) -
Duloxetine in the management of diabetic peripheral neuropathic pain
por: Ormseth, Michelle J, et al.
Publicado: (2011) -
Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain
por: Quilici, Sibilia, et al.
Publicado: (2009)